Walleye Trading’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,900
| Closed | -$89K | – | 4517 |
|
|
2025
Q4 | $89K | Sell |
9,900
-113,300
| -92% | -$1.56M | ﹤0.01% | 3789 |
|
|
2025
Q3 | $2.13M | Sell |
123,200
-31,800
| -21% | -$392K | ﹤0.01% | 1771 |
|
|
2025
Q2 | $1.45M | Buy |
155,000
+135,500
| +695% | +$1.11M | ﹤0.01% | 1938 |
|
|
2025
Q1 | $139K | Buy |
+19,500
| New | +$197K | ﹤0.01% | 3252 |
|
|
2024
Q3 | – | Sell |
-3,800
| Closed | -$85K | – | 4438 |
|
|
2024
Q2 | $85K | Sell |
3,800
-4,200
| -53% | -$100K | ﹤0.01% | 3427 |
|
|
2024
Q1 | $220K | Sell |
8,000
-15,400
| -66% | -$428K | ﹤0.01% | 3372 |
|
|
2023
Q4 | $713K | Sell |
23,400
-15,700
| -40% | -$451K | ﹤0.01% | 2762 |
|
|
2023
Q3 | $1.24M | Sell |
39,100
-3,000
| -7% | -$116K | ﹤0.01% | 2186 |
|
|
2023
Q2 | $1.72M | Sell |
42,100
-50,500
| -55% | -$2.05M | 0.01% | 1765 |
|
|
2023
Q1 | $3.45M | Sell |
92,600
-27,000
| -23% | -$1.06M | 0.01% | 1316 |
|
|
2022
Q4 | $4.17M | Buy |
119,600
+19,100
| +19% | +$908K | 0.01% | 1181 |
|
|
2022
Q3 | $5.62M | Buy |
100,500
+45,700
| +83% | +$2.84M | 0.02% | 954 |
|
|
2022
Q2 | $2.84M | Buy |
54,800
+900
| +2% | +$45.7K | 0.01% | 1398 |
|
|
2022
Q1 | $3.92M | Buy |
53,900
+31,300
| +138% | +$2.65M | 0.01% | 1158 |
|
|
2021
Q4 | $2.67M | Buy |
22,600
+4,800
| +27% | +$601K | 0.01% | 1397 |
|
|
2021
Q3 | $2.39M | Buy |
17,800
+10,100
| +131% | +$1.53M | 0.01% | 1459 |
|
|
2021
Q2 | $1.25M | Sell |
7,700
-3,900
| -34% | -$304K | ﹤0.01% | 1914 |
|
|
2021
Q1 | $931K | Buy |
+11,600
| New | +$779K | ﹤0.01% | 1977 |
|
|
2020
Q1 | – | Sell |
-10,600
| Closed | -$156K | – | 4367 |
|
|
2019
Q4 | $156K | Hold |
10,600
| – | – | ﹤0.01% | 3334 |
|
|
2019
Q3 | $142K | Buy |
+10,600
| New | +$169K | ﹤0.01% | 3149 |
|
|
2019
Q2 | – | Sell |
-18,900
| Closed | -$323K | – | 4348 |
|
|
2019
Q1 | $323K | Buy |
18,900
+3,600
| +24% | +$53.7K | ﹤0.01% | 2649 |
|
|
2018
Q4 | $209K | Buy |
15,300
+11,700
| +325% | +$217K | ﹤0.01% | 3357 |
|
|
2018
Q3 | $103K | Sell |
3,600
-32,100
| -90% | -$934K | ﹤0.01% | 4197 |
|
|
2018
Q2 | $977K | Buy |
35,700
+22,900
| +179% | +$555K | 0.01% | 2129 |
|
|
2018
Q1 | $270K | Buy |
12,800
+6,100
| +91% | +$150K | ﹤0.01% | 3212 |
|
|
2017
Q4 | $130 | Buy |
+6,700
| New | +$155K | ﹤0.01% | 3713 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
Walleye Trading's NTLA Position: Q1 2026 in Review
Walleye Trading sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 11,663 shares — an estimated $105K sold.
Walleye Trading first reported a position in NTLA in Q4 2017 and held it in 13 quarters. The position peaked at $5.14M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.
- Walleye Trading reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
- Walleye Trading sold 11,663 Intellia Therapeutics shares in Q1 2026, an estimated $105K.
- Walleye Trading first reported a position in Intellia Therapeutics in Q4 2017 and held it in 13 quarters.
- Walleye Trading's Intellia Therapeutics position peaked at $5.14M in Q2 2021.
- 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.